ONC vs RPRX: BeiGene and Royalty Pharma Plc compared
The short version
From the latest prices and each company's SEC filings. Who's ahead on each measure, not which to buy.
- BeiGene is the larger company, worth $34.1B, close to Royalty Pharma Plc's $32.3B.
- BeiGene grew revenue faster over the last year (+29.6% vs +16.5%).
- Royalty Pharma Plc keeps more of each dollar of revenue as operating profit (59.6% vs 15.1%).
- On earnings, Royalty Pharma Plc is the cheaper stock (29.5x vs 74.1x).
Side by side
The stronger figure is shaded where higher (or, for valuation multiples, lower) reads as better. How the implied growth works.
| Measure | ONC | RPRX |
|---|---|---|
| Market cap | $34.1B | $32.3B |
| Share price | $354.47 | $56.93 |
| Revenue (last fiscal year) | $5.3B | $2.4B |
| Free cash flow (last fiscal year) | $942M | — |
| Revenue growth, last year | +29.6% | +16.5% |
| Revenue growth per year, last 5 fiscal years | +46.0% | +1.0% |
| Operating margin | 15.1% | 59.6% |
| Net margin | 10.7% | 32.1% |
| Return on equity | 12.7% | 8.3% |
| P/E (trailing) | 74.1x | 29.5x |
| Price / free cash flow | 36.2x | 13.0x |
| EV / EBITDA | 31.5x | 19.1x |
| FCF growth the price implies | 12.7% | — |
| Dividend yield | — | 1.6% |
| Debt / equity | 0.77x | 1.03x |
| Fundamental grade | B | C |
| Superinvestors holding it | 1 | 3 |
| Insider purchases, last 12 months | 0 | 0 |
Results from SEC filings
Revenue and free cash flow by fiscal year, from each company's 10-K filings.
BeiGene
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $1.2B | -$1.6B | -122.3% |
| 2022 | $1.4B | -$1.8B | -126.4% |
| 2023 | $2.5B | -$1.7B | -49.1% |
| 2024 | $3.8B | -$633M | -14.9% |
| 2025 | $5.3B | $942M | 8.4% |
Royalty Pharma Plc
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $2.3B | — | 62.5% |
| 2022 | $2.2B | — | 13.7% |
| 2023 | $2.4B | — | 63.4% |
| 2024 | $2.3B | — | 57.1% |
| 2025 | $2.4B | — | 65.6% |
Where the revenue comes from
BeiGene · by products, 2025
Product revenue, net$5.3B99%
Other revenue$61M1%
Royalty Pharma Plc · by products, 2025
Income from financial royalty assets$2.3B95%
Other royalty income and revenues$117M5%
Compare them in fullFifteen years of statements, quarterly results, DCF and IRR models, and any number of peers side by side.
Open ONC in InvestinglyQuestions
Which is bigger, BeiGene or Royalty Pharma Plc?
BeiGene (ONC), at $34.1B against $32.3B.
Is ONC or RPRX cheaper?
By trailing P/E, Royalty Pharma Plc (29.5x) is cheaper than BeiGene (74.1x). A lower multiple can also mean the market expects less growth.
Which grows faster, ONC or RPRX?
BeiGene: revenue grew +29.6% over the last year, against +16.5%.
Prices and ratios as of the last daily update; statements from SEC filings. Information only, not investment advice.